We have studied the interaction of pregnenolone sulphate and pregnenolone with 5␤-pregnanoloneand hexobarbitone-induced anaesthesia in male rats using an EEG threshold method. Burst suppression of the EEG of 1 s or more ("silent second" (SS)), was used as a criterion of deep anaesthesia. The effects of the steroid solvents albumin and ␤-cyclodextrin were assessed by dose-response curves. Despite a significant increase in hexobarbitone threshold dose in relation to increased doses of albumin, there was no correlation between albumin dose and hexobarbitone concentrations in serum, fat and brain tissues. There was no significant difference in threshold concentrations of hexobarbitone between controls given albumin and those pretreated with pregnenolone. In subsequent experiments, 20% ␤-cyclodextrin was used as steroid solvent and its volume was maintained at less than 3.0 ml kg 91 during pretreatment. Neither pregnenolone sulphate nor pregnenolone significantly altered the potency of 5␤-pregnanolone for induction of anaesthesia. Furthermore, there was no interaction of pregnenolone sulphate and pregnenolone on induction of anaesthesia when hexobarbitone was used for anaesthesia. (Br.
The synthesis of steroid hormones in endocrine tissues begins with cholesterol side chain cleavage (P450scc) which converts cholesterol to pregnenolone (5-pregnen-3␤-ol-20-one). 3␤-Hydroxysteroid dehydrogenase/isomerase converts pregnenolone to progesterone. Progesterone metabolites that are reduced in the 5-position of the steroid molecule are very potent CNS depressants, particularly those with a 3␣-hydroxy-20-ketone structure. 5␤-Pregnanolone (3␣-hydroxy-5␤-pregnan-20-one) is a naturally occurring anaesthetic which accumulates in the brain and interacts with central GABA A receptors as agonist. 1 Pregnenolone and its sulphate ester pregnenolone sulphate have been shown to be synthesized in glial cells in the brain via side chain cleavage of cholesterol. Brain concentrations appear to be independent of gonadal and adrenal synthesis. 1 Electrophysiological studies revealed that pregnenolone sulphate interacts with the GABA A receptor as antagonist. 1 In vivo, Majewska and coworkers 2 found that pregnenolone sulphate antagonized barbiturate-induced anaesthesia in rats, while Melchior and Alien 3 observed that pregnenolone sulphate enhanced barbiturate-induced depression in motor activity without affecting anaesthesia. The aim of this study was to evaluate the interaction of pregnenolone and pregnenolone sulphate with 5␤-pregnanolone-and hexobarbitone-induced anaesthesia. In addition, we investigated the effects of the solvents albumin and ␤-cyclodextrin on induction of anaesthesia.
Methods and results
A previously described EEG threshold method (see Korkmaz, Ljungblad and Wahlström 4 for references) was used to induce anaesthesia with hexobarbitone and 5␤-pregnanolone. Anaesthetics were infused into the tail vein at a constant dose rate. The EEG was monitored continuously via subcutaneous electrodes. The infusion was terminated when the first burst of EEG suppression for 1 s or more was noted (the "silent second", SS). The appearance of SS occurs at a deeper level of anaesthesia than loss of righting reflex. The amount of anaesthetic needed to induce SS was calculated and considered as the threshold dose. A dose rate curve was generated by repeated measurements of threshold doses with different dose rates. The dose rate which gave the lowest threshold dose at SS was defined as the optimal dose rate. Data are expressed as mean (SD) and software SPSS was applied for data analysis.
After obtaining Ethics Committee approval a preliminary study was carried out to examine the effect of the solvent, albumin, on hexobarbitone-induced anaesthesia. 91 in rats given the highest volume of albumin was also found in albumin controls (F 2,19 :22.86, P:0.05). Two-way ANOVA revealed no significant difference in threshold doses of hexobarbitone between pregnenolone pretreated rats and controls (F 2,19 :0.05, P:0.96). The rats were killed at SS and hexobarbitone concentrations in serum, fat, occipital cortex, cerebellum, mid-brain and medulla oblongata were measured by HPLC and UV spectrophotometry, essentially according to a method described in detail previously. 4 Although there was a significant increase in hexobarbitone threshold doses in relation to increased dose of albumin, there was no significant correlation between albumin dose and hexobarbitone concentrations in serum, fat and brain tissues for either controls or pregnenolone pretreated rats ( fig. 1) . Furthermore, there was no significant difference in hexobarbitone concentrations in any tissue between controls and pregnenolone pretreated rats (F 3,85 :1.71, P:0.17, two-way ANOVA).
We used 130 male rats (mean weight 328 (12) g, aged 65-70 days) to examine the interaction of pregnenolone and pregnenolone sulphate (Sigma, MI, USA) with 5␤-pregnanolone-(CoCensys, Inc., Irvine, CA, USA) induced anaesthesia. Pregnenolone 5.0 mg ml 91 , pregnenolone sulphate 6.0 mg ml 91 and 5␤-pregnanolone 4.0 mg ml 91 were dissolved in 20% ␤-cyclodextrin (Sigma, MI, USA) (␤-cyclodextrin 2.0 g in 10 ml of distilled water) in 15-ml aliquots. They were placed in the Bransonic 2210 ultrasonic bath for 15 h and agitated occasionally. After exposure to sonication, all steroids were wetted by visual inspection. Cyclodextrins are cyclic oligosaccharides consisting of 6-8 glucose units which can form inclusion compounds with guest molecules and thereby improve drug solubility and bioavailability.
The relationship between threshold doses of 5␤-pregnanolone at SS and dose rate used for infusion of 5␤-pregnanolone was determined (n:14). The volume rate of the 5␤-pregnanolone infusion was 0.35 ml min , 15 min before infusion of 5␤-pregnanolone (n:25). A significant increase in 5␤-pregnanolone threshold doses was observed at SS which was related to the volume of ␤-cyclodextrin (F 3,24 :9.62, P:0.005, two-way ANOVA). However, 5␤-pregnanolone threshold was not significantly altered by 20% ␤-cyclodextrin pretreatment at 3.0 ml kg 91 compared with untreated controls (least-significant difference test). In order to avoid an effect of the vehicle, the amount of ␤-cyclodextrin used during pregnenolone and pregnenolone sulphate pretreatment was maintained at less than 3.0 ml kg
91
. Doses of pregnenolone 3.5, 7.0 and 14.0 mg kg 91 were tested. Pregnenolone sulphate pretreatment was performed at doses of 4.5, 9.0 and 18.0 mg kg 91 , which were equimolar to the corresponding doses of pregnenolone. Eight rats were used in each dose group. As a control, eight rats were pretreated with ␤-cyclodextrin 3.0 ml kg 91 in both the pregnenolone and pregnenolone sulphate parts of Figure 1 Relationship between threshold concentrations of hexobarbitone at silent second (serum g ml 91 , fat and brain tissue (g g 91 ) and dose of albumin in vehicle controls given albumin (A) and rats pretreated with pregnenolone (B). L:Serum; ᭝:fat; G:medulla oblongata; :midbrain;
:occipital cortex; :cerebellum.
the experiment. We found that neither pregnenolone nor pregnenolone sulphate significantly altered the threshold doses of 5␤-pregnanolone at SS (F 3,27 :1.07, P:0.38 and F 3,27 :0.43, P:0.74, respectively) ( fig. 2) . Doses of pregnenolone 14.0 mg kg 91 (n:9) and pregnenolone sulphate 18.0 mg kg 91 (n:9) were also used to study the interaction of the two neurosteroids with hexobarbitone-induced anaesthesia. As a control, nine rats were pretreated with ␤-cyclodextrin 3.0 ml kg 
Comment
We have previously used a protein vehicle, albumin, as steroid solvent and observed that an albumin preparation of 5␣-pregnanolone was more potent than its lipid preparation in inducing anaesthesia. 5 When we investigated the effect of albumin on the anaesthetic potency of hexobarbitone, threshold doses of hexobarbitone at SS increased in the pregnenolone treated group in the same way as in the control group given the corresponding volume of albumin. However, hexobarbitone concentrations in plasma, fat and four parts of the brain did not change significantly. This indicated that brain sensitivity to hexobarbitone was stable regardless of the increasing doses of albumin. Albumin as a vehicle might cause volume expansion of the blood compartment, thereby diluting the CNS depressant drug in serum. Our results from an interaction study between pregnenolone, pregnenolone sulphate and hexobarbitone differed from those of Majewska and coworkers 2 who observed that pregnenolone sulphate 8.6-16.8 mg kg 91 i.p. reduced pentobarbitoneinduced anaesthesia time by 17-37%. Differences between results obtained when studying induction of anaesthesia compared with those from experiments examining anaesthesia time could be caused by several factors unrelated to changes in brain sensitivity in response to the agents tested, such as elimination rate of the anaesthetic, hypothermia, acute tolerance or pharmacokinetic properties of the substances used during pretreatment. These factors are unrelated to changes in brain sensitivity which may have been induced by the pretreatment.
If pregnenolone sulphate interacts with the steroid recognition site on the GABA A receptor complex and thus alters the sensitivity to anaesthetic agents acting on the GABA A receptor, it would be expected that the sensitivity to 5␤-pregnanolone should be influenced more profoundly than that of barbiturates. 1 However, we studied the influence of pregnenolone and pregnenolone sulphate on induction of 5␤-pregnanolone-induced anaesthesia. However, we found no interaction despite maximal doses clearly within the range used by Majewska and co-workers. 2 The interval between pregnenolone sulphate pretreatment and infusion of 5␤-pregnanolone may be critical for drug interaction. Therefore, we have also studied intervals of 5, 15, 30 and 45 min between pretreatments and 5␤-pregnanolone infusions. The threshold doses at SS did not differ significantly between rats with different delay times (data not shown). The lack of effects in our rat strain could be a result of minimal brain extraction of pregnenolone sulphate because of its low lipophilicity. However, determination of pregnenolone sulphate at SS revealed a concentration of up to 200 ng g 91 in some brain parts in rats pretreated with pregnenolone sulphate 18.0 mg kg 91 (data not shown). This is the concentration at which pregnenolone sulphate may be expected to have effects on the CNS. 6 Furthermore, this concentration of pregnenolone sulphate was approximately 100 times less compared with brain concentrations of 5␣-pregnanolone, a steroid anaesthetic related to 5␤-pregnanolone, at induction of SS with a dose of 8 mg kg 91 . 5 Thus it was not strange that no interaction was observed between pregnenolone sulphate and 5␤-pregnanolone.
Another possibility which could explain the dosedependent antagonistic effect of a pregnenolone sulphate solution is that the vehicle could have increased the volume of the blood compartment, not only in our experiments, but also in those of Majewska and co-workers. 2 Pregnenolone sulphate has been reported to interact with the GABA A receptor in a manner opposite to that of 5␤-pregnanolone in the micromolar concentration range. 1 However, Gee, Joy and Belelli 6 demonstrated that pregnenolone sulphate at submicromolar concentrations had anticonvulsive activity in mice. Some steroids could have both excitatory and anticonvulsive effects in the CNS. It is also possible that the magnitude of the dose could be important as several CNS depressant drugs have excitatory effects at low doses. Figure 2 Relationship between dose of pregnenolone ( ) or pregnenolone sulphate ( ) and threshold doses of 5␤-pregnanolone at silent second.
